Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620774 · ClinicalTrials.gov registry record · Phase 1
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
A Phase 1 study of Diabetes and Healthy Volunteers, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02620774 is a Phase 1 study of Diabetes and Healthy Volunteers that has completed, run by Hartford Hospital. The registered enrollment target is 16 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02620774, a Phase 1 study of Diabetes and Healthy Volunteers, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the tissue penetration of ceftolozane/tazobactam (Zerbaxa, Merck \& Co.), a novel β-lactam/β-lactamase combination antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants.
Conditions Studied
Interventions
- DRUG Ceftolozane/tazobactam
- PROCEDURE Microdialysis Catheter Insertion
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-02-19 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02620774
The ClinicalTrials.gov registry entry for NCT02620774 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Ceftolozane/tazobactam is the first listed.
NCT02620774 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT02620774 about?
NCT02620774 is a clinical study titled "Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections". This study will determine the tissue penetration of ceftolozane/tazobactam (Zerbaxa, Merck \& Co.), a novel β-lactam/β-lactamase combination antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with ...
What is the current status of trial NCT02620774?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-02-19. Estimated completion is 2017-04.
What conditions does trial NCT02620774 study?
This clinical trial studies the following conditions: Diabetes, Healthy Volunteers, Wound Infection.
What interventions are being tested in trial NCT02620774?
The interventions under investigation include: Ceftolozane/tazobactam (DRUG), Microdialysis Catheter Insertion (PROCEDURE).
Who is sponsoring clinical trial NCT02620774?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02620774 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
RECRUITING · Phase 1
-
Insulin Balanced Infusion System
ACTIVE NOT RECRUITING · Phase 1
-
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
COMPLETED · Phase 1
-
Family Management of Childhood Diabetes Study
COMPLETED · Phase 1
-
Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.